Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
MNTX 1109 is a single center, open label study, composed of normal healthy adult subjects to
evaluate the PK of MNTX and its metabolites administered once daily as a subcutaneous (SC)
injection for a period of seven days. Blood samples will be obtained at screening and for
drug concentration data.
Phase:
Phase 1
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.